| 99.32 1.15 (1.17%) | 10-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 122.52 | 1-year : | 143.1 |
| Resists | First : | 104.9 | Second : | 122.52 |
| Pivot price | 94.44  |
|||
| Supports | First : | 88.2 |
Second : | 77.87 |
| MAs | MA(5) : | 99.87 |
MA(20) : | 92.24 |
| MA(100) : | 81.58 |
MA(250) : | 80.28 |
|
| MACD | MACD : | 4.5  |
Signal : | 3.9 |
| %K %D | K(14,3) : | 78.2 |
D(3) : | 85.8 |
| RSI | RSI(14): 62.3 |
|||
| 52-week | High : | 104.9 | Low : | 55.53 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NUVL ] has closed below upper band by 25.6%. Bollinger Bands are 110.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 100.88 - 101.28 | 101.28 - 101.63 |
| Low: | 95.03 - 95.51 | 95.51 - 95.93 |
| Close: | 98.47 - 99.27 | 99.27 - 99.96 |
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Fri, 31 Oct 2025
Barclays Raises Price Target for Nuvalent (NUVL) to $112.00 | NU - GuruFocus
Fri, 31 Oct 2025
Analysts Are Bullish on Top Healthcare Stocks: TransMedics Group (TMDX), Nuvalent (NUVL) - The Globe and Mail
Fri, 31 Oct 2025
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight - GuruFocus
Thu, 30 Oct 2025
Insider Selling: Nuvalent (NASDAQ:NUVL) Director Sells $1,437,799.35 in Stock - MarketBeat
Thu, 30 Oct 2025
Insider Selling: Nuvalent (NASDAQ:NUVL) Director Sells 32,455 Shares of Stock - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 67 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 2.8 (%) |
| Held by Institutions | 109.2 (%) |
| Shares Short | 4,820 (K) |
| Shares Short P.Month | 5,330 (K) |
| EPS | -4.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.4 % |
| Return on Equity (ttm) | -43.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -239 (M) |
| Levered Free Cash Flow | -121 (M) |
| PE Ratio | -20.19 |
| PEG Ratio | 0 |
| Price to Book value | 7.61 |
| Price to Sales | 0 |
| Price to Cash Flow | -27.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|